The present study was designed to determine the effects of theophylline, an adenosine receptor antag onist, and cyclohexyladenosine (CHA), an adenosine re ceptor agonist, on ischemic brain injury following normo and hyperglycemic ischemia and reperfusion in fasted male Wistar rats. Moderate hyperglycemia was achieved by administering 17% n-glucose (3 g/kg i.p.), whereas normoglycemic animals received an equal volume of sa line. The animals were further divided into two groups: One group was pretreated with either theophylline (0.20 fLmollg i.p.) or an equal volume of saline; the second group received either intraventricular CHA (6.25 nmol) or mock CSF prior to the onset of ischemia. During isch emia, pericranial temperature was maintained at 36°C and EEG was monitored. Cerebral ischemia was induced for 15 min, after which flow was restored and the animals were allowed to recover completely. There were no sig nificant differences in physiologic parameters among the groups studied. Five days following the ischemic episode, the rats were perfused with formalin and the brains sub serially sectioned (8 fLm) in the coronal plane and stained
Hyperglycemia aggravates brain injury after tran sient cerebral ischemia and impairs functional neu rologic recovery (Siemkowicz and Hansen, 1978; Pulsinelli et aI., 1982) . Specifically, laboratory stud ies have shown that hyperglycemia is associated with enhanced ischemic tissue injury and reduced postischemic reperfusion (Ginsberg et aI., 1980a; Pulsinelli et aI., 1982; Kagstrom et aI., 1983) . Hy perglycemic ischemia leads to increased tissue lac tic acidosis, and some workers suggest that the in creased tissue lactate and/or excessive cellular with celestine blue/acid fuchsin. Histopathologic analysis was performed in a blinded fashion to determine percent age of dead neurons. Hyperglycemic animals had signif icantly greater ischemic injury in CAl' cortex, and cau date than the normoglycemic group (p < 0.0 l). Moreover, rats pretreated with theophylline had a significantly (p < 0.01) higher percentage of dead neurons in CAl' cortex, and caudate than corresponding controls. On the other hand, rats treated with CHA exhibited significantly (p < 0.0 1) less cerebral ischemic injury than corresponding controls, in either normo-or hyperglycemic conditions. These data confirm previous studies showing the delete rious effects of hyperglycemia on cerebral ischemia reperfusion injury. Moreover, our results illustrate a pro tective effect of adenosine on both normo-and hypergly cemic ischemia-reperfusion injury and thus support the hypothesis that attenuated cerebral ischemic production of adenosine contributes to increased tissue injury ob served under hyperglycemic conditions. Key Words: Adenosine-Cyclohexyladenosine-Ischemia-Theoph ylline.
acidosis leads to enhanced hyperglycemic ischemic injury (Kagstrom et aI., 1983; Kraig and Chesler, 1990) . Others, however, maintain that a clear cause and effect has not been established between in creased tissue acidosis and increased tissue injury (Hoffman et aI., 1990) . Thus, other causative fac tors may contribute to the enhanced cerebral isch emic injury observed under hyperglycemic condi tions.
We have recently shown that under moderate hy perglycemic conditions, ischemic brain adenosine production is decreased in whole tissue as well as in extracellular fluid (Hsu et aI., 1991) . Adenosine, a potent vasodilator (Berne et aI., 1974; Winn et aI., 1981) , may also function as an endogenous neuro protector. Adenosine has multiple neuroprotective actions (Rudolphi et aI., 1992) . Aside from its action as a cerebral vasodilator, adenosine has been shown to decrease neuronal activity (Phillis et aI., 1975) , suppress the release of excitatory amino ac ids (Andine et aI., 1990; Hagberg et aI., 1990) , and attenuate neutrophil activation (Cronstein et aI., 1985) , as well as inhibit neutrophil-endothelial in teractions (Cronstein et aI., 1986) . Additional evi dence supporting the role of adenosine as an endog enous neuroprotector relates to observations that theophylline, an adenosine receptor antagonist, en hances ischemic injury in the hippocampus (Rudol phi et aI., 1987) . Moreover, cyclohexyladenosine (CHA), an adenosine Al agonist, has been shown to protect against ischemic neuronal cell death in the hippocampus (von Lubitz et aI., 1988) .
No prior studies have tested the effects of the ophylline or CHA on ischemic brain injury in hy perglycemic rats. Therefore, in the present study, we investigated the effects of both of these adeno sine receptor agents on cerebral histopathologic in jury in normo-and hyperglycemic rats after tran sient global ischemia.
METHODS

Surgical preparation
This study was approved by the University of Wash ington Animal Care Committee. Experiments were per formed on male Wistar rats weighing 290-310 g, utilizing a four-vessel occlusion model of cerebral ischemia (Pulsinelli and Brierly, 1979) . The animals were anesthe tized initially with 5% halothane in an anesthetizing box and then by means of a mask at 2%. Under an operating microscope, the right and left alar foramina of the first cervical vertebra were carefully exposed and the verte bral artery was gradually cauterized through the foramen using a monopolar electrocautery tip. The wound was closed with 4-0 suture and treated with an antibiotic oint ment. Anesthesia was discontinued and the animals were allowed to recover completely. They were given free ac cess to water but fasted overnight prior to experimenta tion on day 2.
On the following day, the rats were reanesthetized with halothane in the same manner as on day 1. The tail artery was cannulated with PE-50 tubing to monitor MABP and sample blood for determination of blood gases and plasma glucose. The carotid arteries were isolated and scalp EEG electrodes and a needle thermocouple probe (HYP-O; Omega Corp.) were positioned so that EEG and pericra nial temperature could be continuously monitored. Rectal temperature was also monitored and maintained at 36°C throughout the experiment. The thermocouple meter used in these experiments (BAT-4; Bailey Instruments) responds quickly to temperature changes and has a tem perature resolution of 0.20°C. A separate group of ani mals was used to determine the effect, if any, of hyper glycemia, theophylline, and CHA on brain and core temperature during the first 5 h of reperfusion.
Prior to establishing an experimental protocol for CHA, a separate group of experiments was conducted to determine its pharmacokinetics. The rats were anesthe tized with halothane, and the right and left femoral arter ies and the right femoral vein were cannulated to monitor MABP, sample blood, and administer drugs, respec tively. The rats were tracheostomized and blood gases and MABP were allowed to stabilize within physiologic range. CHA (0.0 1 mg/kg i.v.) was administered and blood samples (0.50 ml) were collected at 5, 15, 30, and 60 min following injection. The blood samples were immediately spun and 250 f.LI of plasma removed. The plasma samples were treated with perchloric acid (200 f.LI, 1 N), vortexed, and spun for 10 min. The supernatant was neutralized with KOH, filtered (0.45 f.Lm), and stored in a -70°C freezer to be analyzed by HPLC at a later date.
We also determined the concentration of CHA in the cisterna magna following various doses of CHA injected into the right lateral ventricle. CHA was dissolved in 0. 1 N HCI (0.50 ml) and diluted in mock CSF to reach con centrations of 5 and 500 f.LM. Four groups of animals were studied. The first group of animals was given 25 f.LI of 5 f.LM CHA (0.125 nmol), the second group received 25 f.LI of 500 f.LM CHA (12.5 nmol) , the third group received 12.5 f.LI of 500 f.LM (6.25 nmol), and the fourth group received 2.5 f.LI of 500 f.LM CHA (1.25 nmol) solution. By use of the methods described by Wright and Harding (1980) , cis terna magna CSF was collected 15 min following CHA injection. CSF samples were stored at -70°C for HPLC analysis at a later date.
Experimental protocol
Theophylline group. The rats were randomly assigned to one of four experimental groups: normoglycemic sa line, normoglycemic theophylline, hyperglycemic saline, and hyperglycemic theophylline. Moderate hyperglyce mia was achieved by administering 17% D-glucose (3 g/kg i.p.) 15 min prior to ischemia. The normoglycemic ani mals received an equivalent volume of saline. Thirty min utes prior to the onset of ischemia, the animals received either theophylline (0.20 f.Lmol/g i.p.) or an equivalent vol ume of saline. It has previously been determined that this dose of theophylline reaches peak effective concentra tions in the CSF 30 min following its administration (Morii et ai., 1987) .
CRA group. Our preliminary studies revealed that even low doses (0.0 1 mg/kg) of CHA given systemically signif icantly lower arterial blood pressure (Table 1) . Conse- quently, we chose to deliver the drug into the right lateral ventricle. Based on our CSF collection studies (Table 2) , we decided to inject 6.25 nmol (12.5 /l-l of 500 /l-M) of CHA or an equal volume of CSF intraventricularly. Mod erate hyperglycemia was achieved by administering 17% D-glucose (3 g/kg i.p.) 15 min prior to ischemia, whereas the normoglycemic animals received an equivalent vol ume of saline. The rats utilized in this study were as signed to one of four experimental groups: normoglyce mic CSF, normoglycemic CHA, hyperglycemic CSF, and hyperglycemic CHA. Briefly, the animal's head was fixed in a stereotaxic frame and a l-cm incision was made at the midline. A small burr hole was made 0.80 mm behind the bregma and 1.6 mm from midline. Fifteen minutes prior to the onset of ischemia, either 12.5 /l-l of mock CSF or CHA was injected (4 mm deep) into the lateral ventricle over a period of 5 min.
Ischemia model
Cerebral ischemia was induced for 15 min by occluding the carotid arteries. Halothane anesthesia was discontin ued 3 min prior to the onset of ischemia. A heat lamp was positioned over the animal's head to maintain skull tem perature at 36°C throughout the ischemic episode and in the first hour following ischemia. Complete loss of EEG was observed in all animals used for final data analysis and rats that convulsed during or following ischemia were discarded. At the end of the ischemic episode, flow through the carotid arteries was restored and the wound was closed with 3-0 suture. Arterial blood samples were obtained to determine plasma glucose and blood gases prior to glucose injection, 15 min postinjection (prior to ischemia), and after 10 min of ischemia.
Histologic examination
Five days following the ischemic episode, the animals were reanesthetized, tracheostomized, and ventilated on a respirator. Following a thoracotomy, the ascending aorta was cannulated and the descending aorta occluded. The animal was heparinized (90 IV) and perfused initially with isotonic saline (30 s), followed by 400 ml of a phos phate-buffered formaldehyde solution (4%, pH 7.40) at a constant pressure of 100 mm Hg. The brain was allowed to fix in situ and removed the following day. With use of the methods of Auer et al. (1984) , the brains were sec tioned coronally into 3-mm-thick slices and processed in graded ethanol. The brain slices were embedded in par affin, sub serially sectioned at 8 /l-m, and stained with 0. 1 % cresyl violet followed by 1% acid fuchsin, fortified with a few drops of glacial acetic acid.
Ischemic injury in the hippocampus, cortex, and cau date nucleus was assessed by an investigator blinded to the experimental conditions. The total number of cells and number of dying neurons were counted under high magnification (400x) using a two-channel cell counter (Clay Adams, Parsippany, NJ, V.S.A.). Nuclei or cyto-plasm of necrotic cells stained a brilliant red. Due to the shrinkage of the dying cells, red acidophilic nuclei or cy toplasm was counted in the dying cells, whereas only nuclei were counted in the normal neurons. Hippocampal injury was quantified at two anatomically standardized levels. Injury to the cortex was determined at the level of the subfornical organ. In the caudate nucleus, injury was assessed in the lateral and dorsal aspects at the level of the septal nuclei at their widest point.
HPLC analysis
All plasma and CSF samples were analyzed for CHA by HPLC, using a slightly modified protocol provided by RBI Biochemicals (Natick, MA, V.S.A.). Briefly, sam ples were injected into a Microbondapak (C-18, 10 /l-m) column and eluted with a 20-70% acetonitrile in 50 mM KH2P04 (dibasic) linear gradient at 1 mllmin over 12 min. The retention time and peak height of a known standard were used to identify and calculate the concentration of CHA in each sample.
Statistical analysis
All reported values are expressed as means ± SD. In tergroup differences were determined using a one-way analysis of variance. Fisher's test was applied where ap propriate, and statistical significance was assumed when p < 0.05.
RESULTS
Preliminary studies: CHA concentrations and effects on blood pressure Intravenous administration of CHA (0.01 mg/kg) significantly (p < 0.01) decreased MABP (Table 1) , which remained below control even 30 min after administration. The concentrations of CHA in plasma are also shown in Table 1 . The highest con centration of CHA in plasma (0.16 ± 0.12 flM) was observed at 5 min postinjection, when MABP was lowest (61.3 ± 14 mm Hg). Blood pressure returned to control levels by 60 min postinjection, coincident with lower plasma CHA concentrations.
Because of changes in blood pressure with sys temic CHA, we investigated intraventricular appli cation of CHA. The concentrations of CHA in the cisterna magna CSF following intraventricular ad ministration are shown in Table 2 . Group 1 (25 fll of 5 flM CHA) received a dose that has previously been reported to have beneficial effects in gerbils following cerebral ischemia (von Lubitz et aI., , 1986) . Using a higher concentration of CHA (500 f.LM) and different injection volumes, we measured significantly greater amounts of CHA in the cisterna magna. In our ischemic studies, we chose a dose of CHA (500 f.LM, 12.5-f.LI injection) that produced a cisternal CHA concentration of 0. 37 f.LM 25 min af ter injection. This concentration is -350 times the Kd for CHA. Physiologic variables were monitored and kept constant and within physiologic range.
Since no changes occurred in physiologic variables with intraventricular CHA, in contrast to systemic application, we chose to utilize intraventricular CHA in our subsequent studies.
Histopathology
Histopathologic results for animals treated with either saline or theophylline prior to normo-and hyperglycemic ischemia are depicted in Fig. 1 . Three brain regions, CAl' cortex, and caudate, were analyzed for ischemic injury. Hyperglycemic cerebral ischemia resulted in significantly greater percentage of dead neurons in all three brain re gions than normoglycemia. In addition, the percent age of dead neurons in each of these brain regions was significantly (p < 0.01) greater in theophylline treated rats. Figure 2 depicts the results for animals treated with either intraventricular (12.5 f.Ll) CSF or CHA (6.5 mmol) prior to normo-and hyperglycemic isch emia. Again, hyperglycemia significantly enhanced ischemic injury in hippocampus, cortex, and cau date. The animals treated with CHA had signifi- cantly (p < 0.01) less injury in the three brain re gions analyzed.
Physiologic parameters
Physiologic data prior to and during transient ce rebral ischemia are shown in Tables 3 and 4 . We observed no significant differences among the groups studied for MABP, Pao2, Paco2, arterial pH, and skull or rectal temperature. In all groups, isch emia was accompanied by a transient increase in MABP, a decrease in P aco2, and an increase in pH. However, these responses were consistent among the groups and therefore not significantly different.
Core and brain temperatures during reperfusion remained stable and were not significantly different with hyperglycemia than with normoglycemia (Ta ble 5). In addition, administration of neither theoph ylline nor CHA had an effect on core or brain tem perature.
DISCUSSION
In the present study, we tested the effect of the ophylline and CHA on brain injury in normo-and hyperglycemic rats following transient cerebral ischemia. In normo-and hyperglycemic rats treated with theophylline, the degree of cerebral damage was enhanced. In contrast, animals treated with CHA showed significantly less tissue injury follow ing cerebral ischemia. Thus, our results suggest that adenosine may be an important endogenous cere broprotector under hyperglycemic as well as nor moglycemic conditions. Along with our previous study showing that adenosine concentrations during hyperglycemic ischemia are attenuated as com pared with normoglycemic ischemia (Hsu et aI., Data are presented as means ± SD (n = 6).
1991)
, the present data further support the hypoth esis that attenuated adenosine production during hyperglycemic ischemia and reperfusion contrib utes to increased ischemic injury. During ischemia, elevated blood glucose levels adversely affect neurologic outcome and enhance tissue injury (Nedergaard, 1987) . Recent experi mental findings suggest that postischemic physio logic and/or metabolic alterations may be important in the pathogenesis of increased ischemic injury during hyperglycemia. For example, tissue injury from global (Pulsinelli et aI., 1982) and focal (Ned- Temperature values are expressed as °C and data are presented as means ± SD (n = 3). HO, hyperglycemia (o-glucose, 3 g/kg i.p.); THEO, theophylline (0.20 fLmol/g i.p.); CHA, cyclohexyladenosine (6.25 nmol intraventricularly). ergaard, 1987) ischemia followed by recirculation is enhanced by hyperglycemia. However, with perma nent focal ischemia, hyperglycemia appears to be protective (Ginsberg et aI., 1980b; Zaaslow et aI., 1989) . The mechanism for hyperglycemia-enhanced tissue injury is unclear. Some investigators suggest that increased tissue acidosis and increased lactate production lead to enhanced pathologic injury (Kagstrom et aI. , 1983; Kraig and Chesler, 1990) , whereas other studies do not support a causal role between elevated lactate and subsequent tissue in jury (Hoffman et aI., 1990) .
Based on previous observations of preserved ischemic brain ATP during hyperglycemia as com pared with normoglycemia (Ibayashi et aI., 1986; Hoffman et aI., 1990) , we have demonstrated that the concentrations of adenosine, a product of ATP catabolism, in brain and CSF are attenuated by el evated blood glucose during ischemia (Hsu et aI., 1991) . Adenosine exerts its effects by means of ex tracellular Al and A2 receptors (Fredholm, 1980) and has multiple actions in the brain: vasodilation (Berne et aI., 1974) , depression of electrical activity (Phillis et aI., 1975) , inhibition of the release of ex citatory amino acids (Andine et aI., 1990) , depres sion of neutrophil generation of superoxide anions (Cronstein et aI., 1985) , and attenuation of neutro phil adhesion to endothelial cells (Cronstein et aI., 1986) . Elevated excitatory amino acid concentra tions during ischemia have been implicated in post ischemic cell damage (Rothman, 1984) . Moreover, superoxide anion, generated during reperfusion, may cause direct tissue injury, whereas leukocyte adherence to capillary endothelium impedes micro vascular perfusion (Vedder et aI., 1988) .
The actions of adenosine would therefore protect the brain during ischemia, whereas its relative ab sence would be expected to accentuate brain injury. Furthermore, substances that alter the actions of adenosine would also affect ischemic injury. For example, propentofylline, a novel xanthine deriva tive that inhibits adenosine uptake, potentiates adenosine release and attenuates excitatory amino acid release during ischemia in the rat (Andine et aI., 1990; Hagberg et aI., 1990) . Moreover, this compound significantly reduces neuronal and astro glial changes caused by ischemia (Dux et aI., 1990) . On the other hand, adenosine receptor antagonists have previously been shown to exacerbate normo glycemic ischemic injury (Rudolphi et aI., 1987; Dux et aI., 1990) . Thus, adenosine has been sug gested as an endogenous cerebroprotector during ischemia and reperfusion.
Theophylline has been utilized extensively in pre vious studies designed to evaluate the role of aden osine in the regulation of CBF (Morii et aI., 1987; Ko et aI., 1990) . Although we did not measure CSF theophylline levels in the present experiments, pre vious studies (Morii et aI., 1987) have shown that a dose of 0.20 J.Lmol/g i.p. leads to CSF theophylline concentrations (�10 -4 M) that primarily affect adenosine receptor mechanism(s). Moreover, peak CSF theophylline concentrations are achieved 30 min after injection and remain at peak levels even 60 min postinjection. Our experimental protocol was therefore designed such that effective levels of theophylline in the CSF were attained during the ischemic episode. Following hyperglycemic isch emia, theophylline-treated animals had a signifi cantly greater number of necrotic neurons in hippo campus, cortex, and caudate. The present study thus provides new data on the effect of theophylline on hyperglycemic ischemic injury and confirms pre vious findings under normoglycemic conditions (Rudolphi et aI., 1987; Dux et aI., 1990) . The ad verse effect of theophylline on hyperglycemic isch emic injury is likely due to effective blockade of adenosine receptors, thereby reducing the benefi cial effects of endogenously produced adenosine during ischemia and reperfusion.
CHA, a stable adenosine analogue, has been used as a tool in determining the role of adenosine in cerebral protection. However, unlike theophylline, little is known about its pharmacokinetics. Previous studies in which the drug was administered system ically in rats did not report its effects on blood pres sure (Marangos et aI., 1989) . In gerbils, intraperito neal administration of CHA (2 mg/kg) reportedly depresses MABP by �15 mm Hg (von Lubitz et aI., 1988) . Our preliminary studies on CHA confirmed this hypotensive effect with systemic administra tion, which is presumably due to some A2 receptor effects. Consequently we chose to deliver CHA in traventricularly, utilizing a dose that results in cis ternal CSF concentrations of 0.37 ± 0. 02 J.LM, or 350 times the Kd for CHA. This dose had no effect on arterial blood pressure. Although CHA is rela tively more selective for the adenosine Al receptor, the concentration measured in cisternal CSF (0.37 ± 0.02 J.LM) with intraventricular injection is signif icantly greater than the plasma concentration (0.16 ± 0.12 J.LM) following systemic administration, which significantly reduces arterial blood pressure. Thus, it is likely that CHA, in the present study, is affecting both Al and A2 adenosine receptors.
In the presence of CHA, tissue injury was signif icantly attenuated in hyperglycemic ischemia and reperfusion as compared with corresponding con trols. We also found a protective effect of CHA in normoglycemic ischemia and reperfusion, similar to the observation by von Lubitz et al. (1988) in the gerbil. However, hyperglycemic animals treated with CHA still had greater ischemic injury as com pared with the normoglycemic CHA-treated group. One possible explanation is that ischemia-re perfusion injury is the result of a number of contrib uting factors including excitatory amino acid release, decreased postischemic reperfusion, super oxide anion generation, and neutrophil-endothelial interactions, all of which are improved by adeno sine. Although, as outlined above, CHA may be affecting both Al and A2 adenosine receptors, it may not be present in high enough concentrations in various tissue and/or extracellular compartments to affect all of the factors leading to ischemic injury. For example, it is unlikely that the contribution of neutrophils and/or superoxide anion generation to ischemic injury was affected by intraventricular ad ministration of CHA. Although we did not measure plasma concentration of CHA following intraven tricular administration, the levels achieved were probably insignificant since systemic blood pres sure was unaffected.
In summary, our findings support a role for aden osine as an important cerebroprotector during cere-J Cereb Blood Flow Metab, Vol. 14, No.1, 1994 bral ischemia and reperfusion. Moreover, the present data along with our previous findings of at tenuated ischemic brain adenosine production un der moderate hyperglycemic conditions support the hypothesis that reduced adenosine production is a contributor to hyperglycemia-enhanced ischemic brain injury.
